Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein
- PMID: 23009778
- DOI: 10.1016/j.jacl.2012.04.081
Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein
Abstract
Objective: To characterize the composition of very-low-density lipoprotein (VLDL) particles and the proportion of VLDL to total apolipoprotein B (apoB) particles in patients with hypertriglyceridemia caused by excess VLDL.
Methods: Subjects were selected from 2023 consecutive patients attending the Lipid Clinic at the Laval University Centre. Plasma lipids, apoB, and apoA-I were measured and chylomicron lipids and VLDL and LDL lipids and apoB determined after ultracentrifugation. Patients with hypertriglyceridemia caused by excess VLDL were divided into four groups on the basis of triglyceride and apoB.
Results: A total of 440 controls, 387 subjects with normotriglyceridemic hyperapoB, 38 with type III dysbetalipoproteinemia, 270 with mild hypertriglyceridemic normoapoB, 163 with moderate hypertriglyceridemic normoapoB, 458 with mild hypertriglyceridemic hyperapoB, and 295 subjects with moderate hypertriglyceridemic hyperapoB were compared. In patients with hypertriglyceridemia caused by excess VLDL, the VLDL particles were triglyceride and cholesterol-enriched. HyperapoB is associated with greater low-density lipoprotein (LDL) apoB than normoapoB, whereas greater triglycerides are associated with greater VLDL apoB. Thus, the ratio of VLDL apoB/total apoB was significantly less in those with mild hypertriglyceridemia compared with those with moderate hypertriglyceridemia, irrespective of the plasma apoB.
Conclusions: The apoB phenotypes in hypertriglyceridemia caused by excess VLDL appear to be determined by the extent to which VLDL secretion increases, the extent to which VLDL particles can be converted to LDL particles, and the effects of core lipid exchange. More accurate characterization of hypertriglyceridemia caused by excess VLDL should lead to a better understanding of the determinants of VLDL clearance and conversion to LDL as well as of the atherogenic potential of VLDL.
Copyright © 2012 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1703-7. doi: 10.1161/01.ATV.0000137975.14996.df. Epub 2004 Jul 8. Arterioscler Thromb Vasc Biol. 2004. PMID: 15242863
-
Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.Metabolism. 1999 Mar;48(3):301-7. doi: 10.1016/s0026-0495(99)90076-8. Metabolism. 1999. PMID: 10094104 Clinical Trial.
-
The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.Biol Chem. 2005 May;386(5):441-52. doi: 10.1515/BC.2005.053. Biol Chem. 2005. PMID: 15927888
-
The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia.Curr Opin Lipidol. 2015 Feb;26(1):56-63. doi: 10.1097/MOL.0000000000000146. Curr Opin Lipidol. 2015. PMID: 25551803 Free PMC article. Review.
-
HyperapoB: a pleiotropic phenotype characterized by dense low-density lipoproteins and associated with coronary artery disease.Clin Chem. 1988;34(8B):B71-7. Clin Chem. 1988. PMID: 3042202 Review.
Cited by
-
Maternal cholesterol levels during gestation: boon or bane for the offspring?Mol Cell Biochem. 2021 Jan;476(1):401-416. doi: 10.1007/s11010-020-03916-2. Epub 2020 Sep 22. Mol Cell Biochem. 2021. PMID: 32964393 Review.
-
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors.Am J Cardiovasc Drugs. 2025 Jul 12. doi: 10.1007/s40256-025-00748-7. Online ahead of print. Am J Cardiovasc Drugs. 2025. PMID: 40652105 Review.
-
Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.J Lipid Res. 2018 Jul;59(7):1266-1275. doi: 10.1194/jlr.R082271. Epub 2018 May 16. J Lipid Res. 2018. PMID: 29769239 Free PMC article. Review.
-
Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science.Eur Cardiol. 2020 Jul 15;15:e56. doi: 10.15420/ecr.2019.18. eCollection 2020 Feb. Eur Cardiol. 2020. PMID: 32742310 Free PMC article. Review.
-
The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers.J Lipid Atheroscler. 2019 Sep;8(2):173-182. doi: 10.12997/jla.2019.8.2.173. Epub 2019 Sep 4. J Lipid Atheroscler. 2019. PMID: 32821707 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous